Targeting Aggrephagy for the Treatment of Alzheimer's Disease

Sandeep Malampati, Ju Xian Song, Benjamin Chun-Kit Tong, Anusha Nalluri, Chuan-Bin Yang, Ziying Wang, Sravan Gopalkrishnashetty Sreenivasmurthy, Zhou Zhu, Jia Liu, Chengfu Su, Senthilkumar Krishnamoorthi, Ashok Iyaswamy, King-Ho Cheung, Jia-Hong Lu, Min Li*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

34 Citations (Scopus)


Alzheimer's disease (AD) is one of the most common neurodegenerative diseases in older individuals with specific neuropsychiatric symptoms. It is a proteinopathy, pathologically characterized by the presence of misfolded protein (Aβ and Tau) aggregates in the brain, causing progressive dementia. Increasing studies have provided evidence that the defect in protein-degrading systems, especially the autophagy-lysosome pathway (ALP), plays an important role in the pathogenesis of AD. Recent studies have demonstrated that AD-associated protein aggregates can be selectively recognized by some receptors and then be degraded by ALP, a process termed aggrephagy. In this study, we reviewed the role of aggrephagy in AD development and discussed the strategy of promoting aggrephagy using small molecules for the treatment of AD.

Original languageEnglish
Article number311
Number of pages21
Issue number2
Early online date28 Jan 2020
Publication statusPublished - Feb 2020

Scopus Subject Areas

  • Medicine(all)

User-Defined Keywords

  • aggrephagy
  • selective autophagy
  • Alzheimer’s disease
  • aggregates


Dive into the research topics of 'Targeting Aggrephagy for the Treatment of Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this